表紙
市場調査レポート

EpiCast Report:子宮内膜症の疫学予測

EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 284134
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
EpiCast Report:子宮内膜症の疫学予測 EpiCast Report: Endometriosis - Epidemiology Forecast to 2022
出版日: 2013年09月25日 ページ情報: 英文 38 Pages
概要

世界の主要6ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国)における子宮内膜症の発症件数は、2012年の566万件から、2022年には586万件まで増加する(年間平均増加率3.4%)と予測されています。

当レポートでは、世界の主要6ヶ国における子宮内膜症について取り上げ、危険因子の概要と世界の動向、疫学予測、疫学レポート、疾患動向の分析を提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • 家族歴:子宮内膜症のリスクの強力な予測因子
    • 遅発初経:子宮内膜症の発症から女性を守る
    • 経産回数:多い場合は子宮内膜症のリスクが減少
  • 世界の動向
    • 米国
    • EU5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 子宮内膜症の疫学予測
    • 診断された有病件数
    • 年齢階級別有病件数
    • 年齢調整有病率
    • 診断された有病件数:段階別
  • 議論
    • 疫学予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER030

Summary

Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. Globally, the disease affects up to 10% of women. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding and infertility.

The report provides an overview of the risk factors and global and historical trends for endometriosis in the 6MM. In addition, the report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15-49 years) and stages. GlobalData epidemiologists forecast that the diagnosed prevalent cases of endometriosis in the 6MM will grow from 5.66 million cases in 2012 to 5.86 million cases in 2022, at a growth rate of 3.4% over the forecast period.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of endometriosis in the 6MM, from 5.66 million prevalent cases in 2012 to 5.86 million prevalent case in 2022, at a growth rate of 3.4% over the forecast period. The US constituted the largest proportion (almost 90%) of the prevalent cases of endometriosis, with 5.24 million prevalent cases in 2022. Endometriosis is not a life-threatening condition and is largely influenced by hereditary factors. However, the condition will cause substantial economic, physical and psycho-social burden to the individual, as well as to the healthcare system, during the forecast period.

Scope

  • The Endometriosis EpiCast Report provides an overview of the risk factors and global trends of endometriosis in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15-49 years) and stages.
  • The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
  • Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometriosis therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Family history is a strong predictor for the risk of endometriosis
    • 3.2.2. Late age at menarche protects women from developing endometriosis
    • 3.2.3. Higher parity decreases the risk for endometriosis
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Endometriosis (2012-2022)
    • 3.5.1. Diagnosed Prevalent Cases of Endometriosis
    • 3.5.2. Age-Specific Prevalent Cases of Endometriosis
    • 3.5.3. Age-Standardized Prevalence of Endometriosis
    • 3.5.4. Diagnosed Prevalent Cases of Endometriosis by Stage
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Stages of Endometriosis (as per American Society of Reproductive Medicine)
  • Table 2: Risk Factors for Endometriosis
  • Table 3: Epidemiological Sources for Diagnosed Prevalence and Stages of Endometriosis
  • Table 4: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022
  • Table 5: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, Row (%), 2012
  • Table 6: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stages, Ages 15-49 Years, N, Row (%), 2012

List of Figures

  • Figure 1: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022
  • Figure 2: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, 2012
  • Figure 3: 6MM, Age-Standardized Prevalence (%) of Diagnosed Endometriosis, Ages 15-49 Years, 2012
  • Figure 4: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stage, Ages 15-49 Years, 2012
Back to Top